Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors

Patients with peripheral arterial disease (PAD) are at increased risk for ESRD and cardiovascular events. The primary objective was to assess the association between ankle-brachial index (ABI) values and renal outcome. The secondary objective was to evaluate whether statins and angiotensin-convertin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Society of Nephrology 2007-06, Vol.18 (6), p.1872-1879
Main Authors: FERINGA, Harm H. H, KARAGIANNIS, Stefanos E, BERL, Tomas, POLDERMANS, Don, CHONCHOL, Michel, VIDAKOVIC, Radosav, NOORDZIJ, Peter G, ELHENDY, Abdou, VAN DOMBURG, Ron T, WELTEN, Gijs, SCHOUTEN, Olaf, BAX, Jeroen J
Format: Article
Language:English
Subjects:
Aged
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Disease Progression
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Kaplan-Meier Estimate
Kidney Failure, Chronic - mortality
Kidney Failure, Chronic - physiopathology
Male
Medical sciences
Middle Aged
Multivariate Analysis
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Peripheral Vascular Diseases - drug therapy
Peripheral Vascular Diseases - mortality
Prevalence
Prospective Studies
Renal failure
Risk Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with peripheral arterial disease (PAD) are at increased risk for ESRD and cardiovascular events. The primary objective was to assess the association between ankle-brachial index (ABI) values and renal outcome. The secondary objective was to evaluate whether statins and angiotensin-converting enzyme inhibitors (ACEI) are associated with improved renal and cardiovascular outcome in patients with PAD. In a prospective observational cohort study of 1940 consecutive patients with PAD, ABI was measured and chronic statin and ACEI therapy was noted at baseline. Serial creatinine concentrations were obtained at baseline, 6 mo, and every year after enrollment. End points were ESRD, all-cause mortality, and cardiac events during a median follow-up period of 8 yr. Baseline estimated GFR
ISSN:1046-6673
1533-3450
DOI:10.1681/ASN.2006080887